Registry of pulmonary embolism cases in China

The China Pulmonary Thromboembolism Registry Study (CURES)

This study is collecting information from patients with pulmonary embolism in China to better understand the condition and improve treatment outcomes.

Quick facts

• Study type: Observational
• Enrollment: 15000 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: China-Japan Friendship Hospital (Academic / other)
• Locations: 1 site (Beijing, Beijing)
• Trial ID: NCT02943343 on ClinicalTrials.gov

What this trial studies

The China Pulmonary Thromboembolism Registry Study aims to update and report epidemiological data on pulmonary embolism (PE) in China. This ongoing multicenter registry collects data from patients with suspected or confirmed PE or PE with deep venous thrombosis (DVT) across 100 medical centers. Participants are followed for at least three months to assess their in-hospital outcomes and to gather blood samples for precision medicine research. The study seeks to reveal the etiology and pathogenesis of PE in the Chinese population.

Who should consider this trial

Good fit: Ideal candidates are patients aged 18 years or older with objectively confirmed symptomatic pulmonary embolism or pulmonary embolism with deep venous thrombosis.

Not a fit: Patients younger than 18 years or those without confirmed medical evidence of PE or DVT will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance understanding of pulmonary embolism and improve patient outcomes through better-targeted treatments.

How similar studies have performed: Other studies have shown success in similar registry approaches, indicating the potential for valuable insights into pulmonary embolism.

Eligibility criteria

Patients aged 18 years or above who are admitted to the 100 participating medical centers with suspected PE or PE with DVT are potentially eligible participants and consecutively enrolled in this registry.

Inclusion criteria:

* Objectively confirmed symptomatic PE or PE with DVT patients aged 18 years or above;
* Be able to provide written or verbal informed consent to participation.

Exclusion criteria:

* Younger than 18 years;
* Participation in a therapeutic clinical trial with an unknown drug;
* Inability for at least three-month follow-up since July 2011;
* Suspected PE or PE with DVT patients admitted to the hospital whereas without confirmed medical evidence;
* Patients with a history of PE or DVT readmitted to the hospital for examination or treatment however with no evidence of acute episode or recurrence;
* Withdrawal or lack of informed consent.

Where this trial is running

Beijing, Beijing

• China-Japan Friendship Hospital — Beijing, Beijing, China (Recruiting)

Study contacts

• Principal investigator: Zhenguo Zhai, Ph.D, MD — China-Japan Friendship Hospital
• Study coordinator: Zhenguo ZHAI, Ph.D, MD

Conditions Pulmonary Embolism; Deep Venous Thrombosis; Venous Thromboembolism; Pulmonary embolism; Deep venous thrombosis; Venous thromboembolism; Registry; Real-world study